Eisai Co., Ltd. (ESAIY)
OTCMKTS · Delayed Price · Currency is USD
7.11
+0.02 (0.28%)
Aug 1, 2025, 3:58 PM EDT
Accolade Revenue
In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B JPY with 6.42% growth. Eisai had revenue of 188.24B in the quarter ending March 31, 2025, a decrease of -1.19%.
Revenue
789.40B JPY
Revenue Growth
+6.42%
P/S Ratio
1.53
Revenue / Employee
72.31M JPY
Employees
10,917
Market Cap
8.09B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Eisai News
- 3 days ago - Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds - Reuters
- 7 weeks ago - Eisai: Leqembi Approved In EU (Rating Downgrade) - Seeking Alpha
- 2 months ago - Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 5 months ago - EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug - Reuters
- 5 months ago - Eisai: Will Have No Problem Hitting Leqembi Forecasts - Seeking Alpha
- 6 months ago - Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Europe to review safety data for Eisai-Biogen Alzheimer's drug - Reuters